Indian Medicines Pharmaceutical Corporation Limited (IMPCL) serves as an integral part of India’s healthcare sector, particularly in the traditional medicine segment. Operating under the Ministry of AYUSH, IMPCL has taken a significant role in producing AYUSH medicines, which include Ayurvedic, Unani, and other indigenous medicinal systems prevalent in India. In light of the global COVID-19 pandemic, IMPCL was among the pioneers in supplying immune-boosting medications to help combat the virus. With a diverse range of products, the corporation has achieved a commendable financial milestone, marking its highest-ever turnover in the fiscal year 2020-21.
Introduction to Indian Medicines Pharmaceutical Corporation Limited (IMPCL)
The Indian Medicines Pharmaceutical Corporation Limited is a government-owned entity that specializes in the production of traditional Indian medicines. As a public sector unit, IMPCL operates under the guidance and supervision of the Ministry of AYUSH, which stands for Ayurveda, Yoga & Naturopathy, Unani, Siddha, and Homoeopathy. These systems of medicine are deeply rooted in Indian culture and have been practiced for centuries to treat a wide array of health conditions.
Response to COVID-19
When the COVID-19 pandemic struck, IMPCL swiftly responded by manufacturing and distributing immune-boosting medicines. These medicines were developed based on the principles of AYUSH and aimed to enhance the body’s natural defense mechanisms against the coronavirus. This initiative was in line with the Indian government’s approach to explore all possible avenues, including traditional medicine, to mitigate the impact of the pandemic.
Extensive Product Range
IMPCL boasts an extensive product portfolio that includes 656 classical Ayurvedic medicines, which adhere to the time-honored formulations and methods described in ancient Ayurvedic texts. Additionally, the corporation produces 332 Unani medicines, another traditional system of medicine with roots in Greco-Arabic practices but adapted and evolved within Indian culture. Alongside these, IMPCL also manufactures 71 proprietary Ayurvedic medicines, which are modern therapeutic preparations created based on Ayurvedic concepts and intended for specific health issues.
Adherence to Essential Drug List
All the medicines produced by IMPCL are formulated in accordance with the Essential Drug List (EDL). The EDL is a critical tool for ensuring that essential medicines, which satisfy the priority healthcare needs of the population, are available at all times in adequate amounts and in appropriate dosage forms. By aligning its production with the EDL, IMPCL ensures that its products meet the necessary standards of efficacy, safety, and quality, while also being accessible and affordable.
Record-Breaking Financial Performance
In the fiscal year 2020-21, IMPCL achieved a historic financial milestone by recording its highest-ever turnover of Rs.164.33 crore. This remarkable performance is indicative of the growing demand for AYUSH medicines and the trust placed in IMPCL’s products by consumers. It also reflects the successful expansion of the corporation’s market presence and the effectiveness of its operational strategies during challenging times.
Conclusion
The Indian Medicines Pharmaceutical Corporation Limited plays a pivotal role in the promotion and distribution of traditional Indian medicines. With an impressive array of products and a strong response to public health challenges like the COVID-19 pandemic, IMPCL has demonstrated its importance in the healthcare industry. The corporation’s adherence to the Essential Drug List and its record-breaking turnover further underscore its commitment to providing quality healthcare solutions to the nation. As the world continues to recognize the value of traditional medicine, IMPCL is well-positioned to lead the way in this sector.